Evidence map›Paper›PMID 41648215›Full record

ArticlebioRxiv : the preprint server for biology2026

Ribosome-associated quality control of aberrant protein production during amino acid limitation.

Alicia M Darnell, Christopher Chidley, Victoria Paradise, Danica S Cui, Kristian Davidsen, Sarah C Lincoln, Keene L Abbott, Ryan Elbashir, Campbell P Vander Heiden, Peter K Sorger and 3 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alicia M DarnellKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0003-4633-5722
Christopher ChidleyLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-8212-3148
Victoria ParadiseKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Danica S CuiDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Kristian DavidsenHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0002-3821-6902
Sarah C LincolnKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Keene L AbbottKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-6166-704X
Ryan ElbashirKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Campbell P Vander HeidenKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Peter K SorgerLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-3364-1838
Lucas B SullivanHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0002-6745-8222
Joseph H DavisDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
Matthew G Vander HeidenKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-6702-4192

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9M
Understanding the role of metabolism in cancerR35CA242379 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI VANDER HEIDEN, MATTHEW G. · 2019 to 2025
$5.8M
Understanding metabolic functions of mitochondria in proliferating cellsR35GM147118 · NIGMS · FRED HUTCHINSON CANCER CENTER · PI Lucas Bryan Sullivan · 2022 to 2026
$2.2M
Quantitation and biochemical characterization of autophagy's role in agingR00AG050749 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI DAVIS, JOSEPH HARRY · 2017 to 2019
$744k
NCI NIH HHS P30 CA014051NCI NIH HHS P30 CA015704NCI NIH HHS R35 CA242379NIA NIH HHS R00 AG050749NIGMS NIH HHS R35 GM147118
6 · The paper itself

Abstract

Amino acids can become limiting for protein synthesis through depletion of charged tRNAs, leading to ribosome stalling and disruption of translation elongation at specific codons. To assess whether this is a mechanism by which amino acid availability can directly influence gene expression, we designed a reporter library to measure translation disruption across all sense codons in the context of amino acid limitations. We found that arginine limitation consistently impairs translation at the arginine codon AGA, resulting in synthesis of proteins from endogenous transcripts. In contrast, GCN2 pathway activation suppresses translation disruption following depletion of most other amino acids. Genome-wide screens revealed that the ribosome quality control trigger (RQC-T) and RQC pathways, which resolve ribosome collisions on defective mRNAs, catalyze ribosome splitting and premature fall-off in response to arginine depletion. Additionally, the E3 ubiquitin ligase RNF14, recently shown to clear ribosome A-site obstructions, promotes translation disruption through both ribosome fall-off and frameshifting during arginine limitation. Together, these data show that the RQC machinery is engaged by tRNA-limited ribosomes and identify a new role for RNF14 as a regulator of translation upon arginine limitation.

Identifiers

PMID41648215
PMCPMC12871355

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.